Clinical Report: Survival Prediction Model for Chemotherapy in IMPC of the Breast

Overview

This study developed a survival prediction model for chemotherapy in invasive micropapillary carcinoma (IMPC) of the breast, demonstrating improved overall survival (OS) in high-risk patients. The model was validated externally, highlighting the need for tailored chemotherapy decisions based on risk stratification.

Background

Invasive micropapillary carcinoma (IMPC) is a rare and aggressive breast cancer subtype characterized by high rates of lymphovascular invasion and lymph node metastasis. Current treatment guidelines do not specifically address IMPC, leading to potential overtreatment or undertreatment. Understanding the role of chemotherapy in IMPC is crucial for optimizing patient outcomes.

Data Highlights

Key Findings

• Chemotherapy significantly improved overall survival (OS) in high-risk IMPC patients.
• No significant improvement in breast cancer-specific survival (BCSS) was observed with chemotherapy.
• A risk stratification model was developed incorporating marital status, tumor size, subtype, and radiotherapy history.
• External validation confirmed the model's effectiveness in identifying patients with differential OS outcomes based on chemotherapy.
• Low-risk patients did not benefit from chemotherapy, indicating the need for cautious treatment decisions.

Clinical Implications

The findings underscore the importance of risk stratification in making chemotherapy decisions for IMPC patients. Clinicians should consider individual patient characteristics and the risk model when determining treatment plans to optimize outcomes and avoid unnecessary chemotherapy in low-risk patients.

Conclusion

The study provides a validated model for predicting chemotherapy outcomes in IMPC, emphasizing the necessity of tailored treatment approaches based on risk assessment. Further research is needed to refine these models and improve clinical decision-making.

Related Resources & Content

1. Frontiers in Medicine, 2026 -- Integrating Machine Learning and Clinicopathological Data to Stratify Survival Risk in Young Women with Localized Breast Cancer
2. European Radiology, 2023 -- A predictive model for assessing progression-free survival in advanced non-small cell lung cancer patients following image-guided microwave ablation combined with chemotherapy
3. The ASCO Post, 2021 -- Simulation Model–Based Clinical Decision Tool for Predicting Benefit of Adjuvant Chemoendocrine vs Endocrine Therapy in HR-Positive, HER2-Negative Breast Cancer
4. Frontiers, 2024 -- An overview of invasive micropapillary carcinoma of the breast: past, present, and future
5. SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (UPDATE 2025) - PMC
6. A Predictive Model for Recurrence Risk Following Intravesical Chemotherapy in Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Patients, with External Validation
7. Frontiers | An overview of invasive micropapillary carcinoma of the breast: past, present, and future
8. SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (UPDATE 2025) - PMC
9. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer | New England Journal of Medicine